ERBB2 and neoplasm: Future research should focus on integrating biodegradable or non-toxic quantum dot alternatives to mitigate heavy-metal-related risks, combining HER2-RQDs with complementary therapeutic modalities like photothermal therapy to enhance efficacy, and optimizing nanoprobe pharmacokinetics and tumor penetration to improve treatment outcomes in heterogeneous gastric tumors.